MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Valeri, N
Braconi, C
Gasparini, P
Murgia, C
Lampis, A
Paulus-Hock, V
Hart, JR
Ueno, L
Grivennikov, SI
Lovat, F
Paone, A
Cascione, L
Sumani, KM
Veronese, A
Fabbri, M
Carasi, S
Alder, H
Lanza, G
Gafa', R
Moyer, MP
Ridgway, RA
Cordero, J
Nuovo, GJ
Frankel, WL
Rugge, M
Fassan, M
Groden, J
Vogt, PK
Karin, M
Sansom, OJ
Croce, CM
Braconi, C
Gasparini, P
Murgia, C
Lampis, A
Paulus-Hock, V
Hart, JR
Ueno, L
Grivennikov, SI
Lovat, F
Paone, A
Cascione, L
Sumani, KM
Veronese, A
Fabbri, M
Carasi, S
Alder, H
Lanza, G
Gafa', R
Moyer, MP
Ridgway, RA
Cordero, J
Nuovo, GJ
Frankel, WL
Rugge, M
Fassan, M
Groden, J
Vogt, PK
Karin, M
Sansom, OJ
Croce, CM
Document Type
Journal Article
Date
2014-04-14
Date Accepted
2014-03-06
Abstract
MicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.
Citation
Cancer cell, 2014, 25 (4), pp. 469 - 483
Source Title
Publisher
CELL PRESS
ISSN
1535-6108
eISSN
1878-3686
Collections
Research Team
Signal Transduction & Molecular Pharmacology
Evolutionary Genomics & Modelling
Gastrointestinal Cancer Biology and Genomics
Evolutionary Genomics & Modelling
Gastrointestinal Cancer Biology and Genomics